Evidence map›Paper›PMID 41943831›Full record

ArticleInternational journal of biological sciences2026

Suppression of ASNS expression by VHL-mediated ubiquitination hinders the progression of renal cell carcinoma through enhancing JUP expression and inhibiting PI3K-AKT and MAPK pathways.

Wuping Yang, Tao Liu, Wenwei Ying, Minghao Lu, Dan Xia, Tianyu Tang, Ding Peng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wuping YangDepartment of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Tao LiuDepartment of Urology, Peking University First Hospital, Beijing 100034, China.
Wenwei YingDepartment of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou 310000, China.
Minghao LuDepartment of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Dan XiaDepartment of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Tianyu TangDepartment of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Ding PengDepartment of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal cell carcinoma (RCC) is a metabolic disorder and

Indexed as

Carcinoma, Renal CellKidney NeoplasmsVon Hippel-Lindau Tumor Suppressor ProteinAnimalsCell Line, TumorGene Expression Regulation, NeoplasticHumansMAP Kinase Signaling SystemMiceMice, NudePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktUbiquitinationPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktVHL protein, humanVon Hippel-Lindau Tumor Suppressor Proteinjunction plakoglobinL-AsparagineL-Asparagine synthaserenal cell carcinomaVHL

Identifiers

PMID41943831
PMCPMC13050451

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.